硼替佐米联合地塞米松、沙利度胺治疗初治多发性骨髓瘤疗效观察

目的观察硼替佐米联合地塞米松、沙利度胺治疗初治多发性骨髓瘤（MM）患者的疗效和安全性。方法12例初治MM患者采用硼替佐米联合地塞米松、沙利度胺方案化疗，观察其疗效及不良反应。结果12例初治MM患者总有效率为83．3％，其中非常好的部分缓解4例（33．3％），部分缓解6例（50％）。最常见的不良反应为胃肠道症状、乏力、感染、血小板减少、周围神经病变等，通过对症治疗或停药后均可恢复。结论硼替佐米联合地塞米松、沙利度胺对初治MM患者是一种疗效确切、可以耐受的治疗选择。

Bortezomib with dexamethasone and thalidomide for the treatment of newly diagnosed patients with multiple myeloma

Objective To investigate the efficacy and toxicity of bortezomib with dexamethasone and thalidomide for the treatment of newly diagnosed patients with multiple myeloma. Methods 12 patients with newly diagnosed multiple myeloma were treated by bortezomib with dexamethasone and thalidomide. Efficacy and ADR were observed. Results 12 patients wth newly diagnosed muhiple myeloma of the overall response rate was 83.3% , including 4 very great partial response （33.3%） ,6 partial response （50%）. The most common ADRs were gastrointestinal symptoms, fatigue, infection, thrombocytopenia, peripheral neuropathy. All the ADRs were manageable with symptomatic therapy or stoping drug. Conclusion Bortezomib with dexamethasone and thalidomide is an effective therapy with a high response rate and manageable toxicities for patients with newly diagnosed multiple myeloma.